INS and obesity due to melanocortin 4 receptor deficiency: Apart from lifestyle modifications to reduce obesity through healthy diet and encouragement of physical activity, current pharmacologic therapeutic approaches are based upon increasing insulin availability (either through direct insulin administration or through agents that promote insulin secretion), improving sensitivity to insulin, delaying the delivery and absorption of carbohydrate from the gastrointestinal tract, or increasing urinary glucose excretion [8].